CSTL CASTLE BIOSCIENCES INC
Services-Medical Laboratories · Nasdaq · SEC CIK 1447362 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY-88.1%
TTM EPS YoY-72.7%
Revenue 3-yr CAGR25.2%
Net income 3-yr CAGR—
Margins
Gross margin77.1%
Operating margin-7.4%
Net margin-6.1%
FCF margin1.1%
EBITDA margin-4.4%
Returns
ROE-4.9%
ROA-4.0%
ROIC (approx.)-5.5%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets17.4%
Debt / equity0.02x
Current ratio5.28x
Interest coverage-51.16x
Cash quality & payout
Operating cash flow / net income-1.73x
Accruals ratio-11.0%
Payout ratio—
Capex / revenue9.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $344.23M | $332.07M | $219.79M | $137.04M | $94.08M |
| Cost of revenue | $71.03M | $60.20M | $44.98M | $32.01M | $15.82M |
| Gross profit | $273.20M | $271.86M | $174.81M | $105.03M | $78.26M |
| R&D expense | $51.85M | $52.04M | $53.62M | $44.90M | $29.65M |
| SG&A expense | $229.32M | $200.05M | $180.15M | $143.00M | $86.74M |
| Operating income | -$42.81M | $8.67M | -$67.98M | -$72.86M | -$40.08M |
| Interest expense | $86,000 | $577,000 | $11,000 | $17,000 | $1,000 |
| Income tax | -$5.36M | $3.32M | $101,000 | -$1.77M | -$8.72M |
| Net income | -$24.16M | $18.25M | -$57.47M | -$67.14M | -$31.29M |
| EBITDA | -$2.04M | $24.67M | -$55.65M | -$62.31M | -$36.67M |
| EPS (basic) | -0.83 | 0.66 | -2.14 | -2.58 | -1.24 |
| EPS (diluted) | -0.83 | 0.62 | -2.14 | -2.58 | -1.24 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 28.99M | 29.25M | 26.80M | 26.05M | 25.14M |
| Balance sheet | |||||
| Cash & equivalents | $116.73M | $119.71M | $98.84M | $122.95M | $329.63M |
| Short-term investments | $182.78M | $173.42M | $144.26M | $135.68M | $0 |
| Receivables | $43.38M | $51.22M | $38.30M | $23.48M | $17.28M |
| Inventory | $10.25M | $8.13M | $7.94M | $3.98M | $2.02M |
| Current assets | $361.10M | $360.15M | $295.63M | $292.29M | $353.74M |
| PP&E, net | $97.44M | $51.12M | $25.43M | $14.31M | $9.50M |
| Goodwill | $10.70M | $10.70M | $10.70M | $10.70M | $0 |
| Intangibles | $88.88M | $95.54M | $106.64M | $115.66M | $88.92M |
| Total assets | $578.56M | $531.24M | $453.34M | $447.33M | $462.57M |
| Current liabilities | $68.68M | $49.39M | $47.67M | $36.13M | $24.89M |
| Short-term debt | $417,000 | $278,000 | $0 | — | — |
| Long-term debt | $9.64M | $9.74M | $0 | — | — |
| Total debt | $10.06M | $10.02M | $0 | — | — |
| Total liabilities | $107.68M | $75.40M | $62.07M | $48.18M | $50.83M |
| Shareholders' equity | $470.87M | $455.83M | $391.27M | $399.15M | $411.74M |
| Net debt | -$106.67M | -$109.69M | -$98.84M | — | — |
| Shares outstanding | 29.69M | 28.48M | 27.41M | 26.55M | 25.38M |
| Cash flow statement | |||||
| Operating cash flow | $64.35M | $64.87M | -$5.63M | -$41.66M | -$18.98M |
| Capital expenditure | $36.02M | $28.33M | $13.62M | $5.63M | $3.48M |
| Free cash flow | $28.33M | $36.54M | -$19.25M | -$47.29M | -$22.47M |
| Investing cash flow | -$60.37M | -$50.14M | -$16.18M | -$166.54M | -$66.66M |
| Financing cash flow | -$6.96M | $6.14M | -$2.30M | $1.51M | $5.42M |
| Depreciation & amortization | $40.77M | $16.00M | $12.33M | $10.54M | $3.41M |
| Stock-based compensation | $45.89M | $50.32M | $51.22M | $36.32M | $21.74M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.